
Theodore M. Blum
Examiner (ID: 8545)
| Most Active Art Unit | 2202 |
| Art Unit(s) | 2202, 2200, 2604, 3662, 2607, 3642, 2603 |
| Total Applications | 2205 |
| Issued Applications | 1954 |
| Pending Applications | 86 |
| Abandoned Applications | 165 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19656934
[patent_doc_number] => 20240423999
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => DETOXIFYING AGENT, DETOXIFYING AGENT KIT, AND NOVEL INCLUSION COMPLEX
[patent_app_type] => utility
[patent_app_number] => 18/702178
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10057
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18702178
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/702178 | DETOXIFYING AGENT, DETOXIFYING AGENT KIT, AND NOVEL INCLUSION COMPLEX | Oct 13, 2022 | Pending |
Array
(
[id] => 18375925
[patent_doc_number] => 20230151006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/966696
[patent_app_country] => US
[patent_app_date] => 2022-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53126
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17966696
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/966696 | Substituted pyrazolo-pyridine amides and their use as GluN2B receptor modulators | Oct 13, 2022 | Issued |
Array
(
[id] => 18692497
[patent_doc_number] => 20230322772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-12
[patent_title] => AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/045605
[patent_app_country] => US
[patent_app_date] => 2022-10-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14603
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045605
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045605 | AZAINDOLYLPYRIDONE AND DIAZAINDOLYLPYRIDONE COMPOUNDS | Oct 10, 2022 | Abandoned |
Array
(
[id] => 18361911
[patent_doc_number] => 20230143502
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/960625
[patent_app_country] => US
[patent_app_date] => 2022-10-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 89339
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960625
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/960625 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | Oct 4, 2022 | Issued |
Array
(
[id] => 19722706
[patent_doc_number] => 20250025457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-01-23
[patent_title] => STABLE FORMULATIONS OF BUPRENORPHINE
[patent_app_type] => utility
[patent_app_number] => 18/694487
[patent_app_country] => US
[patent_app_date] => 2022-09-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694487
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/694487 | STABLE FORMULATIONS OF BUPRENORPHINE | Sep 29, 2022 | Pending |
Array
(
[id] => 20134883
[patent_doc_number] => 20250241927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-31
[patent_title] => MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN
[patent_app_type] => utility
[patent_app_number] => 18/694663
[patent_app_country] => US
[patent_app_date] => 2022-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19896
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694663
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/694663 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Sep 28, 2022 | Pending |
Array
(
[id] => 19769897
[patent_doc_number] => 20250051323
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-13
[patent_title] => BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/696506
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19212
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18696506
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/696506 | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | Sep 27, 2022 | Pending |
Array
(
[id] => 19641299
[patent_doc_number] => 20240415819
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/694432
[patent_app_country] => US
[patent_app_date] => 2022-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53259
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694432
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/694432 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Sep 24, 2022 | Pending |
Array
(
[id] => 19134503
[patent_doc_number] => 11969412
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-30
[patent_title] => Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza
[patent_app_type] => utility
[patent_app_number] => 17/951651
[patent_app_country] => US
[patent_app_date] => 2022-09-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 23
[patent_no_of_words] => 21187
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17951651
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/951651 | Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza | Sep 22, 2022 | Issued |
Array
(
[id] => 19599492
[patent_doc_number] => 20240390372
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => METHODS OF TREATING HAIR-LOSS DISORDERS WITH TYK2 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/694424
[patent_app_country] => US
[patent_app_date] => 2022-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694424
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/694424 | METHODS OF TREATING HAIR-LOSS DISORDERS WITH TYK2 INHIBITORS | Sep 21, 2022 | Pending |
Array
(
[id] => 18239529
[patent_doc_number] => 20230071840
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => HETEROCYCLIC GLP-1 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/950098
[patent_app_country] => US
[patent_app_date] => 2022-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53436
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17950098
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/950098 | HETEROCYCLIC GLP-1 AGONISTS | Sep 21, 2022 | Abandoned |
Array
(
[id] => 19598716
[patent_doc_number] => 20240389596
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => INSECT, ACARINA AND NEMATODE PEST CONTROL
[patent_app_type] => utility
[patent_app_number] => 18/694597
[patent_app_country] => US
[patent_app_date] => 2022-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 63
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18694597
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/694597 | INSECT, ACARINA AND NEMATODE PEST CONTROL | Sep 21, 2022 | Pending |
Array
(
[id] => 19027279
[patent_doc_number] => 11926626
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Heterocyclic GLP-1 agonists
[patent_app_type] => utility
[patent_app_number] => 17/950073
[patent_app_country] => US
[patent_app_date] => 2022-09-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53333
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 560
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17950073
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/950073 | Heterocyclic GLP-1 agonists | Sep 20, 2022 | Issued |
Array
(
[id] => 18361292
[patent_doc_number] => 20230142883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => COMPOUNDS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/933330
[patent_app_country] => US
[patent_app_date] => 2022-09-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 77261
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933330
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933330 | COMPOUNDS AND USES THEREOF | Sep 18, 2022 | Abandoned |
Array
(
[id] => 18282544
[patent_doc_number] => 20230098016
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION
[patent_app_type] => utility
[patent_app_number] => 17/944757
[patent_app_country] => US
[patent_app_date] => 2022-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5629
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17944757
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/944757 | Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction | Sep 13, 2022 | Issued |
Array
(
[id] => 18299285
[patent_doc_number] => 20230108971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => SALTS AND CRYSTAL FORMS OF OMECAMTIV MECARBIL
[patent_app_type] => utility
[patent_app_number] => 17/929645
[patent_app_country] => US
[patent_app_date] => 2022-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22558
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17929645
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/929645 | Salts and crystal forms of omecamtiv mecarbil | Sep 1, 2022 | Issued |
Array
(
[id] => 19528156
[patent_doc_number] => 20240352058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => STEROIDAL COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/687411
[patent_app_country] => US
[patent_app_date] => 2022-08-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6279
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18687411
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/687411 | STEROIDAL COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Aug 29, 2022 | Pending |
Array
(
[id] => 19496431
[patent_doc_number] => 20240335449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => COMBINATION THERAPY FOR VAV3 CANCER
[patent_app_type] => utility
[patent_app_number] => 18/681723
[patent_app_country] => US
[patent_app_date] => 2022-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24012
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18681723
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/681723 | COMBINATION THERAPY FOR VAV3 CANCER | Aug 8, 2022 | Pending |
Array
(
[id] => 18109498
[patent_doc_number] => 20230002378
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/876938
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 72476
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17876938
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/876938 | Polyheterocyclic compounds as METTL3 inhibitors | Jul 28, 2022 | Issued |
Array
(
[id] => 18020507
[patent_doc_number] => 20220372006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => SOLID STATE FORMS OF PEMAFIBRATE
[patent_app_type] => utility
[patent_app_number] => 17/867735
[patent_app_country] => US
[patent_app_date] => 2022-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4945
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 321
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17867735
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/867735 | SOLID STATE FORMS OF PEMAFIBRATE | Jul 18, 2022 | Abandoned |